China Biologic Products, Inc. (CBPO) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of China Biologic Products, Inc. (NASDAQ:CBPO) from a sell rating to a hold rating in a research note released on Wednesday morning.

According to Zacks, “China Biologic Products, Inc., through its indirect majority-owned subsidiary, is principally engaged in the research, development, production, manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Its subsidiary, Shandong Taibang Biological Products Co. Ltd., operates from its manufacturing facility located in Taian City, Shandong Province. The Company’s principal products include its approved human albumin and immunoglobulin products. These human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases. “

A number of other equities analysts have also weighed in on CBPO. Jefferies Group LLC restated a buy rating on shares of China Biologic Products in a report on Friday, August 4th. BidaskClub lowered shares of China Biologic Products from a sell rating to a strong sell rating in a report on Saturday, August 5th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. China Biologic Products has a consensus rating of Hold and a consensus price target of $137.50.

Shares of China Biologic Products (NASDAQ CBPO) opened at $86.07 on Wednesday. China Biologic Products has a 12-month low of $72.21 and a 12-month high of $122.19. The company has a market capitalization of $2,376.31, a P/E ratio of 19.17, a PEG ratio of 1.41 and a beta of 1.71.

ILLEGAL ACTIVITY WARNING: “China Biologic Products, Inc. (CBPO) Upgraded at Zacks Investment Research” was published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://ledgergazette.com/2017/11/19/china-biologic-products-inc-cbpo-upgraded-at-zacks-investment-research.html.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Jennison Associates LLC raised its holdings in China Biologic Products by 0.8% in the 2nd quarter. Jennison Associates LLC now owns 5,775 shares of the biopharmaceutical company’s stock worth $653,000 after acquiring an additional 44 shares during the last quarter. BlackRock Inc. raised its stake in China Biologic Products by 694.1% during the 1st quarter. BlackRock Inc. now owns 1,508,096 shares of the biopharmaceutical company’s stock valued at $151,007,000 after buying an additional 1,318,183 shares during the last quarter. Geode Capital Management LLC raised its stake in China Biologic Products by 15.4% during the 1st quarter. Geode Capital Management LLC now owns 14,309 shares of the biopharmaceutical company’s stock valued at $1,432,000 after buying an additional 1,906 shares during the last quarter. Goldman Sachs Group Inc. raised its stake in China Biologic Products by 9.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 58,559 shares of the biopharmaceutical company’s stock valued at $5,863,000 after buying an additional 5,091 shares during the last quarter. Finally, Bank of America Corp DE raised its stake in China Biologic Products by 67.3% during the 1st quarter. Bank of America Corp DE now owns 56,118 shares of the biopharmaceutical company’s stock valued at $5,619,000 after buying an additional 22,583 shares during the last quarter. Institutional investors own 73.58% of the company’s stock.

China Biologic Products Company Profile

Get a free copy of the Zacks research report on China Biologic Products (CBPO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply